US biopharma company Marinus Pharmaceuticals (Nasdaq: MRNS) saw its share plummet today after it announced disappointing top-line results from its Phase III clinical trial in adults with drug-resistant focal onset seizures.
In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically-significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications.
Shares of Marinus were down 70.2% at $1.59 early Monday morning, with a consensus analyst price target of $14.60 and a previous 52-week trading range of $4.00 to $20.72.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze